Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations

J Neuromuscul Dis. 2019;6(1):31-41. doi: 10.3233/JND-180346.

Abstract

Long-term glucocorticoid therapy has improved outcomes in patients with Duchenne muscular dystrophy. However, the recommended glucocorticoid dosage suppresses the hypothalamic-pituitary-adrenal axis, leading to adrenal insufficiency that may develop during severe illness, trauma or surgery, and after discontinuation of glucocorticoid therapy. The purpose of this review is to highlight the risk of adrenal insufficiency in this patient population, and provide practical recommendations for management of adrenal insufficiency, glucocorticoid withdrawal, and adrenal function testing. Strategies to increase awareness among patients, families, and health care providers are also discussed.

Keywords: ACTH; Muscular dystrophy; adrenal crisis; adrenal suppression; cortisol; deflazacort; prednisone.

Publication types

  • Review

MeSH terms

  • Adrenal Insufficiency / diagnosis
  • Adrenal Insufficiency / epidemiology
  • Adrenal Insufficiency / physiopathology
  • Adrenal Insufficiency / therapy*
  • Disease Management
  • Glucocorticoids / adverse effects*
  • Glucocorticoids / therapeutic use*
  • Humans
  • Muscular Dystrophy, Duchenne / drug therapy*
  • Muscular Dystrophy, Duchenne / epidemiology
  • Muscular Dystrophy, Duchenne / physiopathology
  • Neuromuscular Agents / adverse effects*
  • Neuromuscular Agents / therapeutic use*
  • Practice Guidelines as Topic
  • Risk Management

Substances

  • Glucocorticoids
  • Neuromuscular Agents